-
Innovation Ranking
NewInnovation Ranking – BT Group Plc
BT Group plc (BT) is a provider of voice and data services. The company services portfolio comprises managed networked IT services, fixed voice and data services, mobility, television, connectivity, and broadband services. BT also offers copper and fiber connections between exchanges and homes and businesses. The company serves to large corporate firms, small and medium-sized enterprises, start-ups, wholesale customers, commercial premises, homes and public sector organizations. It offers services under BT, Openreach, Plusnet, and EE brand names. The company has...
-
Product Insights
NewNet Present Value Model: Bicycle Therapeutics Plc’s BT-1718
Empower your strategies with our Net Present Value Model: Bicycle Therapeutics Plc's BT-1718 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: Bicycle Therapeutics Plc’s BT-5528
Empower your strategies with our Net Present Value Model: Bicycle Therapeutics Plc's BT-5528 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: Bicycle Therapeutics Plc’s BT-8009
Empower your strategies with our Net Present Value Model: Bicycle Therapeutics Plc's BT-8009 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-1718 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-1718 in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-1718 in Sarcomas Drug Details: BT-1718 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-105 in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-105 in Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-105 in Lymphoma Drug Details: BT-1053 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-5528 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-5528 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-5528 in Ovarian Cancer Drug Details: BT-5528 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BT-5528 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-5528 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-5528 in Gastric Cancer Drug Details: BT-5528 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-5528 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-5528 in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-5528 in Bladder Cancer Drug Details: BT-5528 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-5528 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-5528 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-5528 in Pancreatic Cancer Drug Details: BT-5528 is under development for...